Effect of Linagliptin on the Ratio of Apoptosis Regulators in the Model of Non-Alcoholic Fatty Liver Disease in db/db Mice.

Abstract

We studied the effects of dipeptidyl peptidase 4 (DPP4) inhibitor linagliptin on the expression of apoptosis regulator proteins Bcl-2 and Bad in the liver of db/db mice with genetically determined obesity and type 2 diabetes mellitus. The mice received daily linagliptin or saline (placebo) by gavage from week 10 to week 18 of life. In the liver of non-treated mice, the area positively stained for Bad was greater than the area of Bcl-2 expression, which created the conditions for apoptosis activation in liver at this age. Administration of linagliptin decreased Bad stained area and increased Bcl-2 stained area in the liver cells. At the same time, Bad stained area remained larger in treated mice than the area of Bcl-2 expression area, which attested to partial normalization of pro- and antiapoptotic protein balance.

• Authors: S V Michurina, M A Cherepanova, I Yu Ishchenko, S A Arkhipov, V V Klimontov, E L Zav'yalov
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 167 Issue 2 Pg. 210-214 (Jun 2019) ISSN: 1573-8221 [Electronic] United States
• PMID: 31236880 (Publication Type: Journal Article)

Chemical References

• Dipeptidyl-Peptidase IV Inhibitors
• Proto-Oncogene Proteins c-bcl-2
• bcl-Associated Death Protein
• Linagliptin

Topics

• Animals
• Apoptosis (drug effects)
• Diabetes Mellitus, Type 2
• Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)
• Linagliptin (therapeutic use)
• Liver
• Male
• Mice
• Non-alcoholic Fatty Liver Disease (drug therapy, metabolism)
• Obesity (drug therapy, metabolism)
• Proto-Oncogene Proteins c-bcl-2 (metabolism)
• bcl-Associated Death Protein (metabolism)